In vitro transformation of human congenital naevus to malignant melanoma

被引:7
作者
Mehta, RR [1 ]
Bratescu, L [1 ]
Graves, JM [1 ]
Shilkaitis, A [1 ]
Green, A [1 ]
Mehta, RG [1 ]
Das Gupta, TK [1 ]
机构
[1] Univ Illinois, Dept Surg Oncol, Chicago, IL 60612 USA
关键词
melanocytic naevus; melanoma; transformation;
D O I
10.1097/00008390-200202000-00005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Incidence of melanoma is estimated to be growing at the second fastest rate among all cancers in the United States. The progression of the melanocyte to a malignant melanoma Involves various sequential steps: development of benign naevocellular naevus, preneoplastic dysplastic naevus, primary melanoma, and metastatic melanoma. Despite these clearly defined stages, very little is known about the molecular events leading to melanoma progression. We established a human congenital naevus cell line (UISO-CMN-1). UISO-CMN-1 cells were confirmed to have melanocytic origin by S100 immunoreactivity and the presence of melanin granules and melanosomes. UISO-CMN-1 cells, even though they showed structural and numerical abnormalities in karyotype, were non-tumorigenic when transplanted into athymic mice. However, following frequent exposure to ultraviolet C radiation, UISO-CMN-1 cells acquired tumorigenic potential. Transformation of UISO-CMN-1 cells into tumorigenic cells was accompanied by induction of ganglioside-2 expression without any significant changes in cellular ganglioside-3. These transformed and non-transformed UISO-CMN-1 cell lines can serve as excellent research tools for studying the molecular changes associated with melanoma development and progression, and for identifying agents that might prevent development of malignant melanoma. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 27 条
[1]  
ANDO S, 1983, NEUROCHEM INT, V5, P507, DOI 10.1016/0197-0186(83)90043-8
[2]  
Armstrong B K, 1997, Australas J Dermatol, V38 Suppl 1, pS1
[3]   Melanoma risk and residence in sunny areas [J].
Autier, P ;
Dore, JF ;
Gefeller, O ;
Cesarini, JP ;
Lejeune, F ;
Koelmel, KF ;
Lienard, D ;
Kleeberg, UR .
BRITISH JOURNAL OF CANCER, 1997, 76 (11) :1521-1524
[4]   Molecular pathology of melanoma [J].
Bishop, JAN .
CANCER AND METASTASIS REVIEWS, 1997, 16 (1-2) :141-154
[5]   Malignant melanoma in the year 2000 [J].
Burton, RC .
CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (04) :209-213
[6]  
Green A, 1999, J Epidemiol, V9, pS7
[7]   Improving the safety profile of long-term PUVA therapy [J].
Hobbs, J ;
Lebwohl, M ;
Lim, HW .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 41 (03) :496-497
[8]  
HOLTZMANN B, 1987, INT J CANCER, V39, P466
[9]   SURFACE-ANTIGENS OF MELANOCYTES AND MELANOMAS - MARKERS OF MELANOCYTE DIFFERENTIATION AND MELANOMA SUBSETS [J].
HOUGHTON, AN ;
EISINGER, M ;
ALBINO, AP ;
CAIRNCROSS, JG ;
OLD, LJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 156 (06) :1755-1766
[10]   TRANSFORMATION OF NORMAL HUMAN MELANOCYTES AND NON-MALIGNANT NEVUS CELLS BY ADENOVIRUS 12-SV40 HYBRID VIRUS [J].
JAMBROSIC, J ;
MANCIANTI, ML ;
RICCIARDI, R ;
SELA, BA ;
KOPROWSKI, H ;
HERLYN, M .
INTERNATIONAL JOURNAL OF CANCER, 1989, 44 (06) :1117-1123